Profile data is unavailable for this security.
About the company
Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.
- Revenue in CNY (TTM)1.76bn
- Net income in CNY420.34m
- Incorporated2002
- Employees1.73k
- LocationLiaoning Chengda Biotechnology Co LtdNo. 1Xinfang Street, Hunnan New DistrictSHENYANG 110179ChinaCHN
- Phone+86 2 483782632
- Fax+86 2 423789772
- Websitehttp://www.cdbio.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GuangYuYuan Chinese Herbal Medicn Co Ltd | 1.26bn | 121.59m | 9.12bn | 1.81k | 75.04 | 5.93 | -- | 7.25 | 0.2484 | 0.2484 | 2.57 | 3.14 | 0.4701 | 0.7661 | 1.99 | 694,836.90 | 4.96 | -2.10 | 7.42 | -3.16 | 71.43 | 69.74 | 10.56 | -6.00 | 1.16 | 12.91 | 0.1569 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
Jiangsu Kanion Pharmaceutical Co., Ltd. | 4.87bn | 543.34m | 9.24bn | 5.44k | 17.00 | 1.72 | -- | 1.90 | 0.9342 | 0.9342 | 8.39 | 9.22 | 0.6915 | 3.50 | 6.92 | 895,523.30 | 7.82 | 6.68 | 10.54 | 9.49 | 72.55 | 74.02 | 11.31 | 10.28 | 2.23 | -- | 0.00 | 25.57 | 11.88 | 4.94 | 23.54 | 5.33 | -1.87 | 35.99 |
Guobang Pharma Ltd | 5.28bn | 616.22m | 9.33bn | 4.23k | 15.14 | 1.23 | -- | 1.77 | 1.10 | 1.10 | 9.44 | 13.61 | 0.5231 | 2.78 | 8.16 | 1,247,457.00 | 6.08 | 10.36 | 7.86 | 14.24 | 22.91 | 27.49 | 11.63 | 15.01 | 1.82 | -- | 0.2047 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 420.34m | 9.93bn | 1.73k | 23.53 | 1.02 | -- | 5.64 | 1.01 | 1.01 | 4.26 | 23.41 | 0.1743 | 0.7061 | 1.61 | 1,016,911.00 | 4.16 | 10.63 | 4.27 | 11.01 | 81.48 | 85.74 | 23.87 | 39.56 | 20.80 | -- | 0.002 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 10.40bn | 2.55k | 20.27 | 1.32 | -- | 3.81 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
Tibet Rhodiola Pharmaceutical Holding Co | 2.93bn | 810.63m | 10.58bn | 601.00 | 11.70 | 2.22 | -- | 3.61 | 2.81 | 2.81 | 9.65 | 14.76 | 0.6016 | 1.81 | 6.68 | 4,877,892.00 | 16.83 | 12.44 | 23.18 | 15.71 | 93.68 | 90.51 | 27.97 | 20.43 | 2.79 | 7.96 | 0.1716 | 50.41 | 22.69 | 24.98 | 116.56 | 30.01 | -1.48 | 48.97 |
Zhejiang Medicine Co., Ltd. | 8.04bn | 425.74m | 10.64bn | 6.23k | 24.75 | 1.09 | -- | 1.32 | 0.447 | 0.447 | 8.41 | 10.13 | 0.6329 | 2.91 | 5.57 | 1,290,409.00 | 2.14 | 4.32 | 2.75 | 5.68 | 31.16 | 36.57 | 3.39 | 6.28 | 1.62 | 5.95 | 0.0819 | 58.72 | -3.96 | 2.59 | -20.37 | 3.34 | 12.65 | 0.00 |
Data as of Jul 05 2024. Currency figures normalised to Liaoning Chengda Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
GF Securities Asset Management (Guangdong) Co., Ltd.as of 11 Mar 2024 | 2.75m | 1.54% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.58m | 1.44% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.29m | 1.28% |
The Vanguard Group, Inc.as of 06 Jun 2024 | 881.03k | 0.49% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 738.51k | 0.41% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 620.20k | 0.35% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 595.79k | 0.33% |
Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 564.56k | 0.32% |
China Asset Management Co., Ltd.as of 31 Dec 2023 | 552.30k | 0.31% |
China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 328.04k | 0.18% |
More ▼
Data from 31 Dec 2023 - 03 Jul 2024Source: FactSet Research Systems Inc.